News|Computed Tomography (CT)| April 27, 2022

Choice of oral contrast agent and adequacy of preparation impact detection of intra-abdominal nonsolid malignant deposits on CT, although NPV remains suboptimal

66-Year-Old Man With Locally Advanced Pancreatic Cancer Undergoing Chemotherapy

66-Year-Old Man With Locally Advanced Pancreatic Cancer Undergoing Chemotherapy:(A)使用阳性口腔造影剂的增强CT轴向图像,用于监测治疗反应。检查临床解释为未显示转移性疾病。非盲法回顾性影像学检查显示肠袢附近有微小网膜结节(箭头)。对比剂检查肠道充盈情况良好。两组盲法回溯性读者均检出结节。(B) 2个月后CT增强轴位图显示结节轻微增大(箭头)和几个新结节(箭头),确认为未发现的恶性沉积。Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)


April 27, 2022 —According to ARRS’American Journal of Roentgenology(AJR), the selection of oral contrast agent and optimization of bowel preparation for oncologiccomputed tomography(CT) could help avoid potentially severe clinical consequences of missed malignant deposits.

“CT has suboptimal NPV for malignant deposits in intraabdominal nonsolid organs,” wrote corresponding authorBenjamin M. Yehof theUniversity of California, San Francisco. “Compared to neutral material, positive oral contrast material improves detection, particularly with adequate bowel filling.”

Yeh and team’s retrospective study included 265 patients (133 men, 132 women; median age, 61 years) who underwent anabdominopelvic CTexamination where the report did not suggest presence of malignant deposits and subsequent CT examination within 6 months where the report indicated at least one unequivocal malignant deposit. Examinations used positive (iohexol; n=100) or neutral (water; n=165) oral agents. While reviewing images to assess visibility of deposits, a board-certified abdominal radiologist also assessed adequacy of bowel filling with oral contrast material.

NPV of CT for detection of malignant deposits in intraabdominal nonsolid organs was 65.8% for examinations using positive oral contrast material with adequate bowel filling, 45.2% for positive oral contrast material with inadequate bowel filling (p=.07), and 35.2% for neutral oral contrast material regardless of adequacy of bowel filling (p=.002).

“Results may differ when studying other types of contrast material regimens,”the authors of thisAJRarticle noted, including barium-based, hyperosmolar iodine, sugar-alcohol neutral, or experimental dark oral agents.

For more information:www.arrs.org

Related Content

News|Radiology Imaging

August 11, 2022 — Bracco Imaging S.p.A. has announced the renewal of the “Bracco Fellowships” initiative, in partnership ...

TimeAugust 11, 2022
arrow
The SpeedBird and Concorde device platforms are based on TransMed7’s patented Zero5 work element composed of a fused, single element constructed from 3 hypotubes, laser cut and welded to form articulable twin cutter blades at the end of a rotating open tube
News|Ultrasound Imaging

August 10, 2022 — Butterfly Network, Inc., a digital health company transforming care with handheld, whole-body ...

TimeAugust 10, 2022
arrow
Research has potential to address significant unmet need, identify biomarkers that determine response to treatment
News|Lung Imaging

2022年8月10日—西奈山大学领导的一个肺癌研究团队获得了一项为期三年、价值50万美元的奖金……

TimeAugust 10, 2022
arrow
Mindray solidifies its position as an industry innovator and leader in the POCUS market with the debut of the newest edition to the TE Series Ultrasound Family, the TE X
News|Point-of-Care Ultrasound (POCUS)

August 10, 2022 — Mindray North America, a global leader and developer of healthcare technologies and solutions for ...

TimeAugust 10, 2022
arrow
Bot Image, an Omaha-based MRI medical device company has developed an AI-driven medical device CAD software to significantly improve the accuracy and speed of prostate cancer detection (CADe) and diagnosis (CADx).
News|Prostate Cancer

August 9, 2022 — Bot Image, an Omaha-based MRI medical device company has developed an AI-driven medical device CAD ...

TimeAugust 09, 2022
arrow
The U.S. Food and Drug Administration approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV infusion for the treatment of patients with unresectable (unable to be removed) or metastatic (spread to other parts of the body) HER2-low breast cancer.
News|2022世界杯篮球预选赛赛程

August 8, 2022 — The U.S. Food and Drug Administration approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV ...

TimeAugust 08, 2022
arrow
Dr. Milena Cavic, Institute for Oncology and Radiology of Serbia
News|Lung Imaging

August 8, 2022 — Representatives from the Diagnostics Working Group of the IASLC Early Detection and Screening Committee ...

TimeAugust 08, 2022
arrow
David Gerber, MD
News|Lung Imaging

August 8, 2022 — A clinical trial is only as powerful as its participants. For years, researchers have struggled to fill ...

TimeAugust 08, 2022
arrow
Under this collaboration, IBA will equip the proton therapy system and the proton gantry treatment room at the Fred Hutchinson Cancer Center with ConformalFLASH research functionality, which will enable preclinical research on FLASH therapy.
News|Proton Therapy

August 5, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, Fred ...

TimeAugust 05, 2022
arrow
Chest with AI Brightness and Contrast (AIBC), using Helix 2.2 Advanced Imaging Processing.
News|X-Ray

August 5, 2022 — GE Healthcare released its most advanced fixed X-ray system yet, the next-generation Definium 656 HD ...

TimeAugust 05, 2022
arrow
Subscribe Now